Despite Researcher Criticism, EpicGenetics' Fibromyalgia Test Does $750K in Sales in First Month | GenomeWeb

Biotech startup EpicGenetics last month launched its FM/A protein biomarker test for fibromyalgia with the aim of providing an objective method of diagnosing what has traditionally been a difficult to pin down disease.

Based on research published in December in the journal BMC Clinical Pathology, the test has drawn criticism from several rheumatologists and fibromyalgia researchers who have questioned whether the underlying data supporting it is sufficient.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.